Cargando…

OR16-2 Steroid Receptor Co-Activator Complexes Regulate Metabolic PFKFB Enzymes to Drive Therapy Resistant ER+ Breast Cancer

Recurrence of metastatic breast cancer stemming from acquired endocrine and chemotherapy resistance remains a health burden for women with luminal (ER+) breast cancer. ER+ tumor cells can remain viable but quiescent for years to decades. Contributing factors to metastatic spread include the survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benner, Elizabeth, Dos Santos, Camila, Hagen, Kyla, Lange, Carol, Ostrander, Julie, Temiz, Nuri, Trousdell, Marygrace, Truong, Thu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Tumor Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629109/ http://dx.doi.org/10.1210/jendso/bvac150.1821

Ejemplares similares

PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer
por: Truong, Thu H., et al.
Publicado: (2021)

Steroid Receptor Co-Activators Regulate Metabolic Kinases to Drive Therapy Resistant ER+ Breast Cancer
por: Truong, Thu Ha, et al.
Publicado: (2021)

OR05-04 Steroid Receptor Co-Activators Complexes Cooperate with Progesterone Receptors (PR) to Reprogram Metabolic Pathways that Drive Therapy Resistant Populations in ER+ Breast Cancer
por: Truong, Thu H, et al.
Publicado: (2020)

OR34-1 Regulation of Breast Cancer Stem Cells by Nuclear Receptor Co-Regulatory Proteins
por: Ostrander, Julie, et al.
Publicado: (2019)

Targeting steroid receptor co-activators to inhibit breast cancer stem cells
por: Truong, Thu H., et al.
Publicado: (2018)

OR16-5 Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2022)

Characterization of Organoid Cultures to Study the Effects of Pregnancy Hormones on the Epigenome and Transcriptional Output of Mammary Epithelial Cells
por: Ciccone, Michael F., et al.
Publicado: (2020)

OR16-06 A Novel Pathway Controlling Anticancer Drug Induced Immunogenic Necrosis In ERα Positive Cancer Cells
por: Zhu, Junyao, et al.
Publicado: (2023)

OR16-01 A Common WNT4 Polymorphism Drives Gynecologic Cancer Phenotypes And Health Disparities
por: Bitler, Benjamin G, et al.
Publicado: (2023)

OR34-2 SREBP1 Drives KRT80-Dependent Cytoskeletal Changes and Invasive Behaviour in Endocrine-Resistant ERα Breast Cancer
por: Perone, Ylenia, et al.
Publicado: (2019)

EMBR-16. SMOOTHENED-ACTIVATING LIPIDS DRIVE RESISTANCE TO CDK4/6 INHIBITION IN HEDGEHOG-ASSOCIATED MEDULLOBLASTOMA
por: Daggubati, Vikas, et al.
Publicado: (2021)

THU559 3D Immuno-smFISH Reveals ER-responsive Cells At The Single-cell Level In ER(+) Breast Cancer
por: Kammel, Laura G, et al.
Publicado: (2023)

THU556 Targeting Breast Cancer Stem Cells With Oncolytic Virus
por: Roman Ortiz, Natasha Ivelisse, et al.
Publicado: (2023)

Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer
por: Dasgupta, Subhamoy, et al.
Publicado: (2018)

THU477 Drivers Of Estrogen Induced Invasive Lobular Carcinoma
por: Ufondu, Chinasa, et al.
Publicado: (2023)

ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors
por: Mogol, Ayca, et al.
Publicado: (2022)

SUN-931 Characterization of an Ovarian Steroid Cell Tumor in a VHL Patient
por: Nocito, Marta Claudia, et al.
Publicado: (2020)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2020)

MON-312 Biochemical Basis of Steroid Hormones Action on Human Melanoma Cell Growth In-Vitro and Its Clinical Implication
por: Ramaraj, Pandurangan
Publicado: (2019)

THU555 Stress Induced AIPB Expression In Triple Negative (ER-/PR-/Her2-) Breast Tumors Reduces Estradiol
por: Patrawala, Mahjabin, et al.
Publicado: (2023)

MON-337 A Case Study: Steroid and Gonadotropin Hormones Secretion Pattern in Ovarian Cancer: 10-Year Follow-Up
por: Ezeiruaku, Ferdinand
Publicado: (2019)

Thyroid Hormone and Estrogen Promote Endocrine Resistance, Proliferation, Dedifferentiation, and Cancer Stem Cells in Steroid Receptor-Positive Breast Cancers
por: Wahdan-Alaswad, Reema S, et al.
Publicado: (2021)

EMBR-20. ELONGATION CONTROL OF MRNA TRANSLATION DRIVES GROUP 3 MEDULLOBLASTOMA
por: Delaidelli, Alberto, et al.
Publicado: (2021)

SUN-133 Intratumoral Expression of Steroid Receptors, CD68+ Macrophages and Mdm2 in Different Molecular-Biological Types of Endometrial Cancer
por: Berstein, Lev M, et al.
Publicado: (2020)

OR16-04 Androgen Deprivation Restricts Anti-tumor Immunity In Adrenocortical Carcinoma
por: Warde, Kate M, et al.
Publicado: (2023)

OR05-05 Lethal ERα-Dependent Hyperactivation of the Unfolded Protein Response Induces Complete Regression Without Recurrence of Primary and Metastatic Breast Cancer
por: Duraki, Darjan, et al.
Publicado: (2020)

Assessment of Steroid Hormones in Both Saliva and Blood During a Phase 2 Clinical Trial for the Use of Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia
por: Keevil, Brian, et al.
Publicado: (2021)

Roles of PFKFB3 in cancer
por: Shi, Linlin, et al.
Publicado: (2017)

Nuclear ErbB-2-Induced Transcriptome Drives Triple Negative Breast Cancer Growth
por: Chervo, Maria F, et al.
Publicado: (2021)

Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions
por: Okabe, Seiichi, et al.
Publicado: (2022)

OR16-05 25-Hydroxycholesterol Mediates The Effects Of Dyslipidemia On Triple Negative Breast Cancer Metastasis
por: Etella, Abora, et al.
Publicado: (2023)

OR16-02 Histone ADP-Ribosylation Site Mutations As Oncogenic Drivers In Breast And Ovarian Cancers
por: Huang, Dan, et al.
Publicado: (2023)

ODP558 Steroid Receptor Coactivators Promote Non-Small Cell Lung Cancer Tumorigenesis by Inhibiting Differentiation Factors, C/EBPα and NF-κB
por: Mendelson, Carole, et al.
Publicado: (2022)

Simultaneous inhibition of the estrogen receptor and 6-phosphofructo-2-kinase (PFKFB3) for the treatment of ER+ breast cancer
por: Imbert-Fernandez, Yoannis, et al.
Publicado: (2014)

MON-314 Insulin-like Growth Factor 2 Drives Hepatocellular Carcinoma In Hepatocyte Srsf3 Ko Mice
por: Kumar, Deepak, et al.
Publicado: (2019)

SAT-133 Breast Tumor Kinase (Brk/PTK6) Mediates Triple Negative Breast Cancer Cell Migration and Taxol Resistance via SH2 Domain-Dependent Activation of RhoA and AhR
por: Dwyer, Amy Renee, et al.
Publicado: (2020)

OR16-03 Epigenetic Studies Of Pancreatic Neuroendocrine Tumours (PNETs) Reveal Decreased DNA Hydroxymethylation In Non-functioning PNETs But Not Insulinomas
por: English, Katherine A, et al.
Publicado: (2023)

SUN-336 Autocrine / Paracrine Growth Hormone (GH) Drives Multimodal Therapy Resistance in Growth Hormone Receptor (GHR)-expressing Human Cancers
por: Basu, Reetobrata, et al.
Publicado: (2019)

THU486 Identification Of Metabolic And Molecular Mechanisms Driving Estrogen Receptor Positive Breast Cancer Disparities Using A Machine-Learning Pipeline
por: Casiano, Ashlie Santaliz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ruut015eu9n9u48tjeji7rhkp3